{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:02:16Z","timestamp":1784541736575,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,20]]},"DOI":"10.7759\/cureus.112995","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:06:46Z","timestamp":1784538406000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Addition of Topical Tapinarof for Residual Psoriatic Lesions During Apremilast Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Nao","family":"Kawano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths CE","year":"2021","unstructured":"Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. Lancet. 2021, 397:1301-15. 10.1016\/S0140-6736(20)32549-6","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita J","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017, 76:377-90. 10.1016\/j.jaad.2016.07.064","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020, 323:1945-60. 10.1001\/jama.2020.4006","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16443","article-title":"Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period","volume":"34","author":"Megna M","year":"2020","unstructured":"Megna M, Fabbrocini G, Camela E, Cinelli E. Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period. J Eur Acad Dermatol Venereol. 2020, 34:e705-7. 10.1111\/jdv.16443","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0287-7","article-title":"Topical corticosteroid-induced skin atrophy: a comprehensive review","volume":"38","author":"Barnes L","year":"2015","unstructured":"Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf. 2015, 38:493-509. 10.1007\/s40264-015-0287-7","journal-title":"Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING\u00a03 trial","volume":"87","author":"Strober B","year":"2022","unstructured":"Strober B, Stein Gold L, Bissonnette R, et al.. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING\u00a03 trial. J Am Acad Dermatol. 2022, 87:800-6. 10.1016\/j.jaad.2022.06.1171","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15596","article-title":"Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: results from a phase 2b randomized trial","volume":"48","author":"Imafuku S","year":"2021","unstructured":"Imafuku S, Nemoto O, Okubo Y, Komine M, Schafer P, Petric R, Ohtsuki M. Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: results from a phase 2b randomized trial. J Dermatol. 2021, 48:80-4. 10.1111\/1346-8138.15596","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez204","article-title":"Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis","volume":"58","author":"Mavropoulos A","year":"2019","unstructured":"Mavropoulos A, Zafiriou E, Simopoulou T, et al.. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. Rheumatology (Oxford). 2019, 58:2240-50. 10.1093\/rheumatology\/kez204","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette R","year":"2021","unstructured":"Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021, 84:1059-67. 10.1016\/j.jaad.2020.10.085","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith SH","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, et al.. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017, 137:2110-9. 10.1016\/j.jid.2017.05.004","journal-title":"J Invest Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041618","article-title":"The aryl hydrocarbon receptor (AHR): peacekeeper of the skin","volume":"26","author":"Dawe HR","year":"2025","unstructured":"Dawe HR, Di Meglio P. The aryl hydrocarbon receptor (AHR): peacekeeper of the skin. Int J Mol Sci. 2025, 26:1618. 10.3390\/ijms26041618","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.12.013","article-title":"Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a\u00a0clinical review","volume":"154","author":"Silverberg JI","year":"2024","unstructured":"Silverberg JI, Boguniewicz M, Quintana FJ, et al.. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a\u00a0clinical review. J Allergy Clin Immunol. 2024, 154:1-10. 10.1016\/j.jaci.2023.12.013","journal-title":"J Allergy Clin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17792","article-title":"Complete resolution of residual psoriasis by adding tapinarof cream to tildrakizumab: a case report","volume":"52","author":"Yatsuzuka K","year":"2025","unstructured":"Yatsuzuka K, Muto J, Kohri N, Yoshida S, Nishihara K, Shiraishi K, Fujisawa Y. Complete resolution of residual psoriasis by adding tapinarof cream to tildrakizumab: a case report. J Dermatol. 2025, 52:e711-3. 10.1111\/1346-8138.17792","journal-title":"J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl MG","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Strober B, et al.. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021, 385:2219-29. 10.1056\/NEJMoa2103629","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499041-successful-addition-of-topical-tapinarof-for-residual-psoriatic-lesions-during-apremilast-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:06:47Z","timestamp":1784538407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499041-successful-addition-of-topical-tapinarof-for-residual-psoriatic-lesions-during-apremilast-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.112995","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}